Novo Nordisk(US:NVO) Yahoo Finance·2025-11-25 18:37Core Viewpoint - Novo Nordisk has released positive results from a Phase 2 trial of its GLP-1 receptor agonist, amycretin, for Type 2 diabetes, despite recent disappointing results from a Phase 3 trial of oral semaglutide in early Alzheimer's disease [1][4][8]. Novo Nordisk Trial Results - Novo Nordisk is recognized for its drug semaglutide, which treats Type 2 diabetes (Wegovy) and obesity (Wegovy), part of the GLP-1 receptor agonist class, including Eli Lilly's tirzepatide [2]. - The recent Phase 3 trials of oral semaglutide for Alzheimer's did not show superior efficacy over placebo, which was anticipated as a low probability event [3]. Positive Developments - The Phase 2 trial of amycretin resulted in a significant 14.5% weight loss at 36 weeks, combining a once-weekly subcutaneous dosage with a once-daily oral dosage [4]. - Novo Nordisk is advancing amycretin into Phase 3 trials for obesity and expects FDA approval for oral Wegovy by the end of the year [5]. Market Reaction - Despite the positive news regarding amycretin, the stock of Novo Nordisk has declined over the past two days, indicating market skepticism [6].